Evonik stock: Goldman Sachs keeps EUR 20.00 target for Evonik stock

Published on 10/21/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 adjusted EBITDA reached EUR 630.00 million. Evonik stock costs EUR 21.11 on October 21, 2026, up 0.81 percent versus the Xetra close.

Goldman target and results

Goldman Sachs maintained a EUR 20.00 target and Neutral rating for Evonik on October 1, 2026.
Adjusted EBITDA reached EUR 630.00 million in the second quarter of 2026, up 24.00 percent year over year.
Evonik stock costs EUR 21.11 at Lang & Schwarz on October 21, 2026 at 4:02 p.m. CEST, 0.81 percent above the Xetra close of October 20, 2026, 3.34 percent below the 52-week high.
Evonik is scheduled to report third-quarter 2026 results on November 3, 2026.

Börsenhändler im Frankfurter Xetra-Handelssaal mit MDAX-Anzeigetafeln und Candlestick-Charts — Evonik Industries DE000EVNK013 im Börsen-Editorial des Frankfurter Xetra-Handelssaals mit MDAX-Charts und Händlern, Illustration mit AI erstellt.

Evonik (ISIN DE000EVNK013) stock was at EUR 21.11 at Lang & Schwarz on October 21, 2026 at 4:02 p.m. CEST, up 0.81 percent versus the Xetra close of October 20, 2026. According to Finvaulta on October 1, 2026, Goldman Sachs kept a Neutral rating and a EUR 20.00 12-month price target. The target sits 5.26 percent below the price.

Second-quarter earnings set the tone

Evonik reported adjusted EBITDA of EUR 630.00 million for the second quarter of 2026, up 24.00 percent from the same period a year earlier. The figure was above expectations communicated during the first-quarter call, according to Yahoo Finance. Evonik also said adjusted EBITDA reached EUR 1.10 billion in the first half of 2026.

Stock remains below its yearly high

The EUR 21.11 quote is EUR 0.73 below Evonik's 52-week high of EUR 21.84 and EUR 8.62 above its 52-week low of EUR 12.49, both as of October 21, 2026. That places the stock 3.34 percent below the high and 69.02 percent above the low. Trading volume was 92,704 shares in the same quote.

Valuation and reporting date

Evonik had a market capitalization of EUR 9.8 billion and a price-to-earnings ratio of 81.52 as of October 21, 2026. The company investor-relations calendar schedules third-quarter 2026 reporting for November 3, 2026, as stated on Evonik.

Comparison with peers

Evonik: plus 0.81 percent, price-to-earnings ratio 81.52, market capitalization EUR 9.8 billion.

BASF (Xetra, EUR): plus 0.59 percent, price-to-earnings ratio 7.96, market capitalization EUR 45.6 billion. Lanxess (Xetra, EUR): minus 0.73 percent, price-to-earnings ratio minus 1.58, market capitalization EUR 1.1 billion.

What comes next for the stock

The immediate reference point is the November 3, 2026 reporting date, while Goldman Sachs places its 12-month target below the October 21 quote. The contrast between the EUR 630.00 million quarterly adjusted EBITDA and the EUR 20.00 target leaves earnings delivery and valuation as the key figures for the next update.

Evonik stock price and outlook

At EUR 21.11, Evonik stock was 0.81 percent above the Xetra close of October 20, 2026. The quote was 3.34 percent below the 52-week high of EUR 21.84.

The further course of trading is shown by the continuously updated real-time quote of Evonik stock.